Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

accord healthcare b.v. - metotreksatas - injekcinis tirpalas užpildytame švirkšte - 50 mg/ml - methotrexate

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vakcinos - a (h1n1) v 2009 viruso sukeltos gripo profilaktika. celvapan turėtų būti naudojami laikantis oficialių rekomendacijų.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

alfasigma s.p.a. - metiltioninio chlorido - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

photocure asa - heksaminolevulinatas - milteliai ir tirpiklis šlapimo pūslės tirpalui - 85 mg - other diagnostic agents

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocitopenija, idiopatinė - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ir 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ir 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemija, sirupo ląstelė - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

laboratoire innotech international - pirantelis - geriamoji suspensija - 125 mg/2,5 ml; 125 mg; 250 mg - pyrantel

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

laboratoire innotech international - benzalkonio chloridas - makšties minkštosios kapsulės - 54 mg/4,5 g; 12 mg/g; 60 mg; 20 mg; 18,9 mg - intravaginal contraceptives

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

laboratoire innotech international - neomicino sulfatas/polimiksino b sulfatas/nistatinas - makšties minkštosios kapsulės - 35000 tv/35000 tv/100000 tv - nystatin, combinations